DXM, DXO and metabolism

DXM FAQ 1997: selective audit by topic

How enzymes change the balance of DXM and DXO, and why people respond differently.

Five principal metabolic transitions

The diagram shows reactions from the table in audit section 2. The reaction list is not exhaustive.

  1. O-demethylation predominantly by CYP2D6
  2. N-demethylation involving CYP3A
  3. N-demethylation involving CYP3A
  4. O-demethylation involving CYP2D6
  5. Conjugation by UGT enzymes, primarily the UGT2B family

Audit §2: pathways, conjugation and interpretation limits →

DXM and DXO are both pharmacologically active

This point remains valid. Modern evidence clarifies differences between their targets and the contribution of metabolism to effects.

Retained

According to the 2026 audit · edition

Evidence and limitations

What was examined: Studies altering CYP2D6 activity show that shifts in the balance of DXM and DXO change the profile of subjective responses. Xiao’s paper compares target binding in vitro.

Limits of the conclusion: Each substance’s contribution depends on exposure and the study endpoint. Binding data concern the biological system studied; their relevance to effects in humans remains uncertain.

Sources: Zawertailo — metabolism and effects Zawertailo — CYP2D6 inhibition Xiao — DXM and DXO target binding

Historical paraphrase · FAQ 4.0 · 1997 · §5.15 White already described the activity of DXM itself and its metabolite DXO.

This claim in the 2026 audit · Erowid archive (HTML 4.0-Y.1) · §5.15 · Why does DXM Affect Different People So Differently?

CYP2D6 converts DXM to DXO

The main pathway is described correctly. Conversion rates vary with genetic variants of the enzyme and drug inhibition.

Retained

According to the 2026 audit · edition

Evidence and limitations

What was examined: Capon’s pharmacokinetic study and Rüdesheim’s model link CYP2D6 activity to DXM exposure. Zawertailo’s studies also examine subjective effects.

Limits of the conclusion: Interpretation depends on formulation, concomitant medicines and the measure being examined.

Sources: Rüdesheim — pharmacokinetic model Capon — CYP2D6 activity Zawertailo — metabolism and effects Zawertailo — CYP2D6 inhibition

Historical paraphrase · FAQ 4.0 · 1997 · §9.5 The FAQ links DXO formation to CYP2D6.

This claim in the 2026 audit · Erowid archive (HTML 4.0-Y.1) · §9.5 · Pharmacokinetics: How DXM is Metabolized

Poor metabolism and the pattern of effects

With reduced CYP2D6 activity, DXM exposure can increase substantially. The experience also changes: a small study reported greater sedation, dysphoria and psychomotor impairment.

Corrected

According to the 2026 audit · edition

Evidence and limitations

What was examined: Capon examined pharmacokinetics in poor and extensive metabolizers; Zawertailo’s pilot study compared their subjective and psychomotor responses.

Limits of the conclusion: The finding applies to the conditions of these small studies. Genotype accounts for part of the variability, while individual responses also depend on other factors.

Sources: Capon — CYP2D6 activity Zawertailo — metabolism and effects

Historical paraphrase · FAQ 4.0 · 1997 · §9.5 The FAQ suggests that DXM has weaker effects in poor metabolizers.

This claim in the 2026 audit · Erowid archive (HTML 4.0-Y.1) · §9.5 · Pharmacokinetics: How DXM is Metabolized

Modern metabolizer categories

Modern terminology distinguishes PM, IM, NM and UM: poor, intermediate, normal and ultrarapid metabolism. Functional activity of variants and the effects of medicines on actual enzyme activity are considered.

Clarified

According to the 2026 audit · edition

Evidence and limitations

What was examined: Caudle’s consensus standardizes translation of CYP2D6 genotype into phenotype; Rüdesheim’s model applies modern categories to DXM pharmacokinetics.

Limits of the conclusion: The historical label EM requires checking the definition used in the particular study. Enzyme inhibitors can alter the functional phenotype, a process called phenoconversion.

Sources: Rüdesheim — pharmacokinetic model Caudle — CYP2D6 genotype and phenotype

Historical paraphrase · FAQ 4.0 · 1997 · §9.5 White describes differences in CYP2D6 activity and people with extra gene copies.

This claim in the 2026 audit · Erowid archive (HTML 4.0-Y.1) · §9.5 · Pharmacokinetics: How DXM is Metabolized

Correcting an arrow in the metabolic scheme

This pathway starts with DXM: N-demethylation produces 3-methoxymorphinan. The corresponding pathway for DXO leads to 3-hydroxymorphinan.

Corrected

According to the 2026 audit · edition

Evidence and limitations

What was examined: Schemes in Lutz’s and Rüdesheim’s papers distinguish O-demethylation from N-demethylation and subsequent processing of metabolites.

Limits of the conclusion: A specific connection in the scheme is corrected. The FAQ’s other valid descriptions of DXO formation remain applicable.

Sources: William White — historical DXM FAQ Lutz — DXM metabolism Rüdesheim — pharmacokinetic model

Historical paraphrase · FAQ 4.0 · 1997 · §9.5 One sentence in the FAQ attributes formation of 3-methoxymorphinan to DXO.

This claim in the 2026 audit · Erowid archive (HTML 4.0-Y.1) · §9.5 · Pharmacokinetics: How DXM is Metabolized

Further processing of DXO

A modern scheme also includes DXO glucuronidation. Results should distinguish unconjugated DXO, total DXO and the protein-unbound fraction.

Clarified

According to the 2026 audit · edition

Evidence and limitations

What was examined: Lutz’s paper examines how CYP-dependent and subsequent pathways affect assessment of metabolism; Rüdesheim’s model accounts for processing of DXM and DXO.

Limits of the conclusion: The meaning of a measurement depends on the analytical method. Concentrations can be compared after identifying which form of the substance was measured.

Sources: Lutz — DXM metabolism Rüdesheim — pharmacokinetic model

Historical paraphrase · FAQ 4.0 · 1997 · §9.5 The FAQ focuses on the two main demethylation pathways.

This claim in the 2026 audit · Erowid archive (HTML 4.0-Y.1) · §9.5 · Pharmacokinetics: How DXM is Metabolized

Sources for this topic
  1. William White — historical DXM FAQ — Historical archive

    The edition label and date of text version 4.0 and the Erowid HTML archive label (4.0-Y.1) were checked. The archive contains later edits.

  2. Lutz — DXM metabolism — PubMed abstract
  3. Rüdesheim — pharmacokinetic model — PubMed abstract
  4. Capon — CYP2D6 activity — PubMed abstract
  5. Caudle — CYP2D6 genotype and phenotype — PubMed abstract
  6. Zawertailo — metabolism and effects — PubMed abstract
  7. Zawertailo — CYP2D6 inhibition — PubMed abstract
  8. Xiao — DXM and DXO target binding — Selected paper sections

    The abstract, target-binding table and conflict-of-interest disclosure were checked; the authors are employees of the compound’s developer.

All update topics · Review coverage

Reference

Open the source and related combinations →